Stock Track | Burning Rock Soars After NMPA Approves Co-Developed Lung Cancer Companion Diagnostic

Stock Track10-11

Shares of Burning Rock Biotech Limited (NASDAQ: BNR) surged over 5% in after-hours trading on October 10th, 2024, after the company announced a significant regulatory approval for its co-developed companion diagnostic test for lung cancer.

Burning Rock and its partner, biopharmaceutical firm Dizal, jointly revealed that the National Medical Products Administration (NMPA) of China has granted marketing approval to their companion diagnostic test for detecting EGFR exon 20 insertion mutations. This test is specifically designed to be used in conjunction with Dizal's EGFR exon 20 insertion mutation-targeted therapy, sunvozertinib, providing a precision treatment solution for non-small cell lung cancer patients with this specific mutation.

The approved companion diagnostic, known as "LungCure CDx," is an NGS-based test that can detect multiple gene mutations, including EGFR, MET, ERBB2, KRAS, BRAF, PIK3CA, ALK, ROS1, and RET in non-small cell lung cancer patients. This approval marks the first co-developed NGS-based companion diagnostic for lung cancer to receive NMPA clearance since the release of China's companion diagnostic guidelines.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

1

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1144197181?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-11 11:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1144197181","market":"us","top_or_hot":-1,"title":"Stock Track | Burning Rock Soars After NMPA Approves Co-Developed Lung Cancer Companion Diagnostic","media":"Stock Track","content":"<p>Shares of Burning Rock Biotech Limited (NASDAQ: BNR) surged over 5% in after-hours trading on October 10th, 2024, after the company announced a significant regulatory approval for its co-developed companion diagnostic test for lung cancer.</p>\n\n<p>Burning Rock and its partner, biopharmaceutical firm Dizal, jointly revealed that the National Medical Products Administration (NMPA) of China has granted marketing approval to their companion diagnostic test for detecting EGFR exon 20 insertion mutations. This test is specifically designed to be used in conjunction with Dizal's EGFR exon 20 insertion mutation-targeted therapy, sunvozertinib, providing a precision treatment solution for non-small cell lung cancer patients with this specific mutation.</p>\n\n<p>The approved companion diagnostic, known as \"LungCure CDx,\" is an NGS-based test that can detect multiple gene mutations, including EGFR, MET, ERBB2, KRAS, BRAF, PIK3CA, ALK, ROS1, and RET in non-small cell lung cancer patients. This approval marks the first co-developed NGS-based companion diagnostic for lung cancer to receive NMPA clearance since the release of China's companion diagnostic guidelines.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Burning Rock Soars After NMPA Approves Co-Developed Lung Cancer Companion Diagnostic</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Burning Rock Soars After NMPA Approves Co-Developed Lung Cancer Companion Diagnostic\n</h2>\n\n<h4 class=\"meta\">\n\n2024-10-11 11:22 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Burning Rock Biotech Limited (NASDAQ: BNR) surged over 5% in after-hours trading on October 10th, 2024, after the company announced a significant regulatory approval for its co-developed ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BNR","symbol_name":"燃石医学","start_time":0,"source_url":"","article_id":"1144197181","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1144197181","pubTimestamp":1728616947,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Burning Rock Biotech Limited  surged over 5% in after-hours trading on October 10th, 2024, after the company announced a significant regulatory approval for its co-developed companion diagnostic test for lung cancer.Burning Rock and its partner, biopharmaceutical firm Dizal, jointly revealed that the National Medical Products Administration  of China has granted marketing approval to their companion diagnostic test for detecting EGFR exon 20 insertion mutations. This test is specifical","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BNR":"燃石医学"},"translate_title":"NMPA批准共同开发的肺癌伴随诊断后，股票赛道Burning Rock飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNR":1},"content_text":"Shares of Burning Rock Biotech Limited (NASDAQ: BNR) surged over 5% in after-hours trading on October 10th, 2024, after the company announced a significant regulatory approval for its co-developed companion diagnostic test for lung cancer.\nBurning Rock and its partner, biopharmaceutical firm Dizal, jointly revealed that the National Medical Products Administration (NMPA) of China has granted marketing approval to their companion diagnostic test for detecting EGFR exon 20 insertion mutations. This test is specifically designed to be used in conjunction with Dizal's EGFR exon 20 insertion mutation-targeted therapy, sunvozertinib, providing a precision treatment solution for non-small cell lung cancer patients with this specific mutation.\nThe approved companion diagnostic, known as \"LungCure CDx,\" is an NGS-based test that can detect multiple gene mutations, including EGFR, MET, ERBB2, KRAS, BRAF, PIK3CA, ALK, ROS1, and RET in non-small cell lung cancer patients. This approval marks the first co-developed NGS-based companion diagnostic for lung cancer to receive NMPA clearance since the release of China's companion diagnostic guidelines.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1144197181"}